Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods

US Patent 12230398 · Granted Feb 18, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Apparatus and method for identification of primary immune resistance in cancer p2024
Apparatus and method for identification of primary immune resistance in cancer p2024
Apparatus and method for identification of primary immune resistance in cancer p2024
Methods and systems for automatic call data generation2024
Calibrated risk scoring and sampling2024
Using a traffic monitoring service to detect traffic pattern shifts2024
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2024
Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitaliz2024
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy2023